- •Diabetic Retinopathy
- •Preface
- •Acknowledgments
- •Contents
- •Contributors
- •Pathophysiology of Diabetic Retinopathy
- •1.1 Retinal Anatomy
- •1.1.1 History
- •1.1.2 Anatomy
- •1.1.3 Microanatomy of the Retina Neurons
- •1.1.4 Intercellular Spaces
- •1.1.5 Internal Limiting Membrane
- •1.1.6 Circulation
- •1.1.7 Arteries
- •1.1.8 Veins
- •1.1.9 Capillaries
- •1.2 Hemodynamics, Macular Edema, and Starling’s Law
- •1.3 Biochemical Basis for Diabetic Retinopathy
- •1.3.1 Increased Polyol Pathway Flux
- •1.3.2 Advanced Glycation End Products (AGEs)
- •1.3.3 Activation of Protein Kinase C (PKC)
- •1.3.4 Increased Hexosamine Pathway Flux
- •1.4 Macular Edema
- •1.5 Development of Proliferative Diabetic Retinopathy
- •1.6 Summary of Key Points
- •1.7 Future Directions
- •References
- •Genetics and Diabetic Retinopathy
- •2.1 Background for Clinical Genetics
- •2.2 The Role of Polymorphisms in Genetic Studies
- •2.3 Types of Genetic Study Design
- •2.4 Studies of the Genetics of Diabetic Retinopathy
- •2.4.1 Clinical Studies
- •2.4.2 Molecular Genetic Studies
- •2.4.3 EPO Promoter
- •2.4.4 Aldose Reductase Gene
- •2.4.5 VEGF Gene
- •2.5 Genes in or Near the HLA Locus
- •2.6 Receptor for Advanced Glycation End Products (RAGE) Genes
- •2.7 Endothelial NOS2 and NOS3 Genes
- •2.9 Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 1 Gene (SLC2A1)
- •2.11 Potential Value of Identifying Genetic Associations with Diabetic Retinopathy
- •2.12 Summary of Key Points
- •2.13 Future Directions
- •Glossary
- •References
- •Epidemiology of Diabetic Retinopathy
- •3.1 Introduction and Definitions
- •3.2 Epidemiology of Diabetes Mellitus
- •3.3 Factors Influencing the Prevalence of Diabetes Mellitus
- •3.4 Epidemiology of Diabetic Retinopathy
- •3.5 Diabetes and Visual Loss
- •3.6 Prevalence and Incidence of Diabetic Retinopathy
- •3.7 By Diabetes Type
- •3.8 By Insulin Use
- •3.10 By Duration of Diabetes Mellitus
- •3.11 By Ethnicity
- •3.12 Gender
- •3.13 Age at Onset of Diabetes
- •3.14 Socioeconomic Status and Educational Level
- •3.15 Family History of Diabetes
- •3.16 Changes Over Time
- •3.17 Epidemiology of Diabetic Macular Edema (DME)
- •3.18 Epidemiology of Proliferative Diabetic Retinopathy (PDR)
- •3.19 Socioeconomic Impact of Diabetes
- •3.20 Socioeconomic Impact of Diabetic Retinopathy
- •3.21 Summary of Key Points
- •3.22 Future Directions
- •References
- •Systemic and Ocular Factors Influencing Diabetic Retinopathy
- •4.1 Introduction
- •4.2 Systemic Factors
- •4.2.1 Glycemic Control
- •4.2.1.1 Type 1 Diabetes Mellitus
- •4.2.1.2 Type 2 Diabetes Mellitus
- •4.2.1.3 Rapidity of Improvement in Glycemic Control
- •4.2.2 Glycemic Variability
- •4.2.3 Insulin Use in Type 2 Diabetes
- •4.2.5 Blood Pressure
- •4.2.6 Serum Lipids
- •4.2.7 Anemia
- •4.2.8 Nephropathy
- •4.2.9 Pregnancy
- •4.2.10 Other Systemic Factors
- •4.2.11 Influence on Visual Loss
- •4.3 Effects of Systemic Drugs
- •4.3.1 Diuretics
- •4.3.3 Aldose Reductase Inhibitors
- •4.3.4 Drugs That Target Platelets
- •4.3.5 Statins
- •4.3.6 Protein Kinase C Inhibitors
- •4.3.7 Thiazolidinediones (Glitazones)
- •4.3.8 Miscellaneous Drugs
- •4.4 Ocular Factors Influencing Diabetic Retinopathy
- •4.6 Economic Consequences
- •4.7 Summary of Key Points
- •4.8 Future Directions
- •References
- •Defining Diabetic Retinopathy Severity
- •5.1 Summary of Key Points
- •5.2 Future Directions
- •5.3 Practice Exercises
- •References
- •6.1 Optical Coherence Tomography (OCT)
- •6.2 Heidelberg Retinal Tomograph (HRT)
- •6.3 Retinal Thickness Analyzer (RTA)
- •6.4 Microperimetry
- •6.5 Color Fundus Photography
- •6.6 Fluorescein Angiography
- •6.7 Ultrasonography
- •6.8 Multifocal ERG
- •6.9 Miscellaneous Modalities
- •6.10 Summary of Key Points
- •6.11 Future Directions
- •6.12 Practice Exercises
- •References
- •Diabetic Macular Edema
- •7.1 Epidemiology and Risk Factors
- •7.2 Pathophysiology and Pathoanatomy
- •7.2.1 Anatomy
- •7.3 Physiology
- •7.4 Clinical Definitions
- •7.5 Focal and Diffuse Diabetic Macular Edema
- •7.6 Subclinical Diabetic Macular Edema
- •7.7 Refractory Diabetic Macular Edema
- •7.8 Regressed Diabetic Macular Edema
- •7.9 Recurrent Diabetic Macular Edema
- •7.10 Methods of Detection of Diabetic Macular Edema
- •7.11 Case Report 1
- •7.12 Case Report 2
- •7.13 Other Ancillary Studies in Diabetic Macular Edema
- •7.14 Natural History
- •7.15 Treatments
- •7.15.1 Metabolic Control and Effects of Drugs
- •7.16 Focal/Grid Laser Photocoagulation
- •7.16.1 ETDRS Treatment of CSME
- •7.17 Evolution in Focal/Grid Laser Treatment Since the ETDRS
- •7.18 Macular Thickness Outcomes After Focal/Grid Photocoagulation
- •7.19 Resolution of Lipid Exudates After Focal/Grid Laser Photocoagulation
- •7.20 Inconsistency in Defining Refractory Diabetic Macular Edema
- •7.21 Alternative Forms of Laser Treatment for Diabetic Macular Edema
- •7.22 Peribulbar Triamcinolone Injection
- •7.23 Intravitreal Triamcinolone Injection
- •7.24 Intravitreal Dexamethasone Delivery System
- •7.27 Combined Intravitreal and Peribulbar Triamcinolone and Focal Laser Therapy
- •7.28 Vitrectomy
- •7.29 Supplemental Oxygen and Hyperbaric Oxygenation
- •7.30 Resection of Subfoveal Hard Exudates
- •7.31 Subclinical Diabetic Macular Edema
- •7.32 Cases with Simultaneous Indications for Focal and Scatter Laser Photocoagulation
- •7.34 Factors Influencing Treatment of Diabetic Macular Edema
- •7.35 Sequence of Therapy
- •7.36 Interaction of Cataract Surgery and Diabetic Macular Edema
- •7.37 Summary of Key Points
- •7.38 Future Directions
- •References
- •Diabetic Macular Ischemia
- •8.1 Introduction
- •8.2 Pathogenesis, Anatomy, and Physiology
- •8.3 Natural History
- •8.4 Clinical Evaluation
- •8.5 Clinical Significance of Diabetic Macular Ischemia
- •8.6 Controversies and Conundrums
- •8.7 Summary of Key Points
- •8.8 Future Directions
- •References
- •Treatment of Proliferative Diabetic Retinopathy
- •9.1 Introduction
- •9.2 Laser Photocoagulation
- •9.2.1 Indications
- •9.2.2 PRP Technique
- •9.2.3 Complications
- •9.2.4 Outcome
- •9.3 Intraocular Pharmacological Therapy
- •9.4 Vitreoretinal Surgery
- •9.4.1 Indications
- •9.4.2 Preoperative Management
- •9.4.3 Instrumentation
- •9.4.4 Techniques
- •9.4.5 Postoperative Management
- •9.4.6 Complications
- •9.4.7 General Outcome
- •9.5 Follow-Up Considerations in PDR
- •9.6.1 Cataract and PDR
- •9.6.2 Dense Vitreous Hemorrhage and Untreated PDR
- •9.6.3 Untreated PDR with Diabetic Macular Edema
- •9.6.4 PDR with Severe Fibrovascular Proliferation/Traction Retinal Detachment
- •9.6.5 PDR with Neovascular Glaucoma
- •9.6.6 Conditions Altering the Clinical Course of PDR
- •9.7 Summary of Key Points
- •9.8 Future Directions
- •References
- •Cataract Surgery and Diabetic Retinopathy
- •10.1 Scope of the Problem of Diabetic Retinopathy Concomitant with Surgical Cataract
- •10.2 Visual Outcomes After Cataract Surgery in Patients with Diabetic Retinopathy
- •10.3 Postoperative Course and Special Considerations After Cataract Surgery in Patients with Diabetic Retinopathy
- •10.4 The Influence of Cataract Surgery on Diabetic Retinopathy
- •10.5 The Role of Ancillary Testing in Managing Cataract Surgery in Eyes with Diabetic Retinopathy
- •10.6 Candidate Risk and Protective Factors for Diabetic Macular Edema Induction or Exacerbation Following Cataract Surgery and Suggested Management Actions
- •10.7 The Problem of Adherence to Preferred Practice Guidelines
- •10.8 Management of the Diabetic Eye Without Macular Edema About to Undergo Cataract Surgery
- •10.9 Treatment of Diabetic Macular Edema Detected Before Cataract Surgery When the Macular View Is Clear
- •10.10 Management When Cataract Sufficient to Obscure the Macular View and DME Coexist or When Refractory DME and Cataract Coexist
- •10.11 Patients with Simultaneous Indications for Panretinal Photocoagulation and Cataract Surgery
- •10.12 Management of Cataract in Patients with Diabetic Retinopathy Undergoing Vitrectomy
- •10.13 Influence of Vitrectomy Surgery on Cataract Formation
- •10.15 Postoperative Endophthalmitis in Patients with Diabetic Retinopathy
- •10.16 Summary of Key Points
- •10.17 Future Directions
- •References
- •The Relationship of Diabetic Retinopathy and Glaucoma
- •11.1 Interaction of Diabetes and Glaucoma
- •11.2 Iris and Angle Neovascularization Pathoanatomy and Pathophysiology
- •11.3 Epidemiology
- •11.4 Clinical Detection
- •11.5 Classification
- •11.6 Risk Factors for Iris Neovascularization
- •11.7 Entry Site Neovascularization After Pars Plana Vitrectomy
- •11.8 Anterior Hyaloidal Fibrovascular Proliferation
- •11.9 Treatments for Iris Neovascularization
- •11.10 Modifiers of Behavior of Iris Neovascularization
- •11.11 Management of Neovascular Glaucoma
- •11.12 Summary of Key Points
- •11.13 Future Directions
- •References
- •The Cornea in Diabetes Mellitus
- •12.1 Introduction
- •12.2 Pathophysiology
- •12.3 Anatomy and Morphological Changes
- •12.4 Clinical Manifestations
- •12.5 Ocular Surgery
- •12.6 Treatment of Corneal Disease in Diabetes Mellitus
- •12.7 Conclusion
- •12.8 Summary of Key Points
- •12.9 Future Directions
- •References
- •Optic Nerve Disease in Diabetes Mellitus
- •13.1 Relevant Normal Optic Nerve Anatomy and Physiology
- •13.2 The Effect of Diabetes on the Optic Nerve
- •13.3 Nonarteritic Anterior Ischemic Optic Neuropathy and Diabetes
- •13.4 Diabetic Papillopathy
- •13.5 Disk Edema Associated with Vitreous Traction
- •13.6 Superior Segmental Optic Hypoplasia (Topless Optic Disk Syndrome)
- •13.7 Wolfram Syndrome
- •13.8 Summary of Key Points
- •13.9 Future Directions
- •References
- •Screening for Diabetic Retinopathy
- •14.1 Introduction
- •14.2 Who Does Not Need to Be Screened
- •14.5 Screening with Dilated Ophthalmoscopy by Ophthalmic Technicians or Optometrists
- •14.6 Screening with Dilated Ophthalmoscopy by Ophthalmologists
- •14.7 Screening with Dilated Ophthalmoscopy by Retina Specialists
- •14.8 Photographic Screening
- •14.9 Nonmydriatic Photography
- •14.10 Mydriatic Photography
- •14.11 Risk Factors for Ungradable Photographs
- •14.12 Number of Photographic Fields
- •14.13 Criteria for Referral
- •14.14 Obstacles to the Use of Teleophthalmic Screening Methods
- •14.15 Combination Methods of Screening
- •14.16 Case Yield Rates
- •14.17 Compliance with Recommendation to Be Seen by an Ophthalmologist
- •14.18 Intravenous Fluorescein Angiography and Oral Fluorescein Angioscopy
- •14.19 Automated Fundus Image Interpretation
- •14.20 Subgroups Needing Enhanced Screening Efforts
- •14.21 Screening in Pregnancy
- •14.22 Economic Considerations
- •14.23 Comparisons of the Screening Methods
- •14.24 Accountability of Screening Programs
- •14.25 Summary of Key Points
- •14.26 Future Directions
- •References
- •Practical Concerns with Ethical Dimensions in the Management of Diabetic Retinopathy
- •15.1 Incorporating Ancillary Testing in the Management of Patients with Diabetic Retinopathy
- •15.2.1 Case 1
- •15.2.2 Case 2
- •15.4 Working in a Managed Care Environment (Capitation)
- •15.5 Interactions with Medical Industry
- •15.7 Comanagement of Patients
- •15.9 Summary of Key Points
- •15.10 Future Directions
- •References
- •Clinical Examples in Managing Diabetic Retinopathy
- •16.1.1 Discussion
- •16.2 Case 2: Bilateral Proliferative Diabetic Retinopathy with Acute Vitreous Hemorrhage in One Eye and a Chronic Traction Retinal Detachment in the Other Eye
- •16.2.1 Discussion
- •16.2.2 Opinion 1
- •16.2.3 Opinion 2
- •16.2.4 Opinion 3
- •16.3 Case 3: Sight Threatening Diabetic Retinopathy in a Patient with Concomitant Medical and Socioeconomic Problems
- •16.3.1 Discussion
- •16.4 Case 4: Asymptomatic Retinal Detachment Following Vitrectomy in a Patient Who Has Had Panretinal Laser Photocoagulation
- •16.4.1 Discussion
- •16.5 Case 5: Management of Progressive Vitreous Hemorrhage Following Scatter Photocoagulation for Proliferative Diabetic Retinopathy
- •16.5.1 Discussion
- •16.6.1 Discussion
- •16.7 Case 7: Proliferative Diabetic Retinopathy with Macular Traction and Ischemia
- •16.7.1 Discussion
- •16.8 Case 8: What Is Maximal Focal/Grid Laser Photocoagulation for Diabetic Macular Edema?
- •16.8.1 Definition of the Problem
- •16.8.2 Discussion
- •16.9 Case 9: What Independent Information Does Macular Perfusion Add to Patient Management in Diabetic Retinopathy?
- •16.9.1 Discussion
- •16.10 Case 10: Macular Edema Following Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
- •16.10.1 Discussion
- •16.11 Case 11: Diabetic Macular Edema with a Subfoveal Scar
- •16.11.1 Discussion
- •16.12.1 Definition of the Problem
- •16.12.2 Discussion
- •16.13.1 Definition of the Problem
- •16.13.2 Discussion
- •16.14 Case 14: How Is Diabetic Macular Ischemia Related to Visual Acuity?
- •16.14.1 Definition of the Problem
- •16.14.2 Discussion
- •References
- •Subject Index
162 |
D.J. Browning |
|
|
Fig. 7.23 Late-phase fluorescein angiogram of the right eye of case 1 in September 2008. There is petalloid hyperfluorescence most prominent superior and temporal to the fovea although the epicenter of the thickening on the OCT false color map is inferonasal to the fovea
refractory DME can be larger than OCT measurement variability, which for an eye with macular thickness of 273 mm would be approximately 30 mm. The clinician may need to include this factor of short-term variability of macular thickness in refractory DME in clinical decision making to avoid restarting previously futile styles of treatment
and possibly inducing further side effects such as laser-induced paracentral scotomata or steroid-
induced pressure elevation without benefiting visual acuity.142,175
7.12 Case Report 2
A 77-year-old man with diabetes of 10 years duration and hypertension of 1-year duration was examined in 2000 and found to have DME reducing visual acuity in the left eye to 20/50. No OCT was available in our clinic in 2000, but clinically significant macular edema was found on stereoscopic slit-lamp biomicroscopy with a noncontact fundus lens and two sessions ofargon laser focal/grid photocoagulation were given on 16 March 2000 and 28 January 2002. The DME resolved both on clinical examination and by OCT measurements once that instrument became available to the practice. During follow-up, four consecutive normal CSMTs were recorded between 25 January 2005 and 21 August 2007 in consonance with the clinical examination that showed no macular thickening on stereoscopic slit-lamp biomicroscopy. The appearance of the fundus at this time is shown in
Fig. 7.24 OCT images of the right eye of case 1 in October 2008 when the patient had spontaneous regression of the exacerbated macular thickening. The radial line scan is oriented vertically
7 Diabetic Macular Edema |
163 |
|
|
Fig. 7.25. At follow-up on 9 April 2008, the CSMT increased to 283 mm compared to the value of 205 mm on 21 August 2007 (Figs. 7.26 and 7.27). Clinically, the center of the macula was judged to be not thickened. The question arose whether the 78 mm increase in macular thickness represented a change in the macula in excess of the short-term fluctuation in macular thickness in an eye with regressed DME. In other words, was this recurrent DME and did it need to be treated?
The patient was observed without treatment and at follow-up on 11 November 2008 was noted to have spontaneous resolution of the macular thickening present at the previous examination. That is, as this case exemplifies, short-term fluctuation in CSMT in regressed DME is potentially larger than OCT measurement variability. For an eye with macular thickness of 205 mm, measurement
Fig. 7.25 Color fundus photograph documenting the appearance of the left eye of case 2 with regressed DME and a pattern of focal/grid laser scars
Fig. 7.26 Three OCT false color maps of the left eye of case report 2 documenting the regional pattern of macular thickness in a patient with regressed DME after two sessions of focal/grid photocoagulation given 7 years earlier. On 8 May
2008, there is OCT thickening that was not present at the 21 August 2007 visit. Without any therapy, there is spontaneous regression of this thickening as shown in the map from 11 November 2008
164 |
D.J. Browning |
|
|
Fig. 7.27 Three OCT horizontal radial line scans documenting the macular morphology of the left eye of case report 2 on the same three dates shown in
Fig. 7.25. On 9 May 2008, there is intraretinal cystoid change and thickening that was not present on 21 August 2007. The thickening has spontaneously resolved by the scan of 11 November 2008, although there is still some lesser degree of intraretinal cystoid change
variability would be approximately 21 mm. The clinician may be advised to include the larger shortterm fluctuation factor for eyes with regressed DME in clinical decision-making.
Of the many OCT indices that can be followed in
the course of DME, the central subfield mean thickness (CSMT) is the best single measure.176,177 It is
more reproducible than center point thickness, yet is highly correlated (r ¼ 0.99) with the latter.176,177
Total macular volume (TMV) correlates somewhat less well with CSMT(r ¼ 0.76), but there have been no conclusions drawn from analyzing TMV that
would not have been drawn by studying CSMT instead.146,157 Other variables such as maximal thick-
ening of the inner zone and maximal thickening of
the grid have not added value to analyses using CSMT.157 OCT has also revealed the fact that serous retinal detachment is associated with DME in
9.7–26.0% of cases, a fact unappreciated in the ETDRS era.68,132,178–180 Serous retinal detachment
can be associated with mild or severe degrees of neural retinal thickening, with retinopathy featuring clustered microaneurysms or with few microaneurysms, and has little correlation with visual acuity impairment. It responds to treatments for DME, just as does the thickening of the neural retina, is not correlated with degree of capillary nonperfusion, and has little prognostic importance for outcome.116 Serous retinal detachment is not seen in the absence of some degree of neural retinal edema.180
Methods of Analysis of OCT Data
OCT-measured changes in macular thickness can be analyzed in three ways – as absolute changes in thickness, relative changes in thickness, and relative changes in thickening, where thickening means excess retinal thickness compared to published normal values. Chan and Duker have stated that all studies of
7 Diabetic Macular Edema |
165 |
|
|
macular edema should employ the relative change in thickening method of analysis, but their recommendations were based on examples from the literature that were much thicker than the majority of eyes treated for DME.177 The DRCR Network has shown that the relative change in thickening method of analysis is unstable for eyes with mild degrees of macular edema—for example, with thicknesses <300 mm (Fig. 7.28). For such eyes, the preferred method of analysis is absolute change in thickness.176
Subfield Thickening |
p.m. (%) |
Change in Central |
from 8 a.m. to 4 |
Relative |
|
100 |
|
|
|
|
|
|
|
|
75 |
|
|
|
|
|
|
|
|
Increase 50 |
|
|
|
|
|
|
|
|
25 |
|
|
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
|
–25 |
|
|
|
|
|
|
|
|
–50 |
|
|
|
|
|
|
|
|
Decrease |
|
|
|
|
|
|
|
|
–75 |
|
|
|
|
|
|
|
|
–100 |
|
|
|
|
|
|
|
|
–125 |
|
|
|
|
|
|
|
|
100 |
200 |
300 |
400 |
500 |
600 |
700 |
800 |
900 |
8 a.m. Central Subfield Thickness (Microns)
Fig. 7.28 Reproduced with permission from Browning.176 Relative change in central subfield thickening from 8 a.m. to 4 p.m. by the 8 a.m. central subfield thickness in a study of
diurnal variation of macular thickness in eyes with diabetic macular edema. 181 When the baseline thickening is small, the scatter in the relative change in thickening becomes large
Optical coherence tomography was originally developed using time domain acquisition of images (TD-OCT).182 More recently, machines using spectral domain acquisition of images have been introduced (SD-OCT), and time domain machines, while prevalent in practice, are no longer being made. Spectral
domain technology allows faster acquisition of images and denser sampling of the macula.183–185
The normal values for SD-OCT and TD-OCT differ
because the segmentation algorithms define the retina layers differently.184,185 TD-OCT defines retinal
thickness as the distance between the internal limiting membrane and the photoreceptor inner segment/ outer segment boundary. SD-OCT defines retinal thickness as the distance between the internal limiting membrane and the retinal pigment epithelial layer. For this reason, retinal thickness values with SD-OCT are on average 50–60 mm thicker than
values with TD-OCT and are tightly correlated (r > 0.9).193–195 The axial resolution of SD-OCT is 2–7 mm compared to 10–15 mm with TD-OCT.184,186,187 This
leads to a more sensitive detection of cystoid changes in the macula with SD-OCT, such that prevalences of such morphologic findings must be qualified by describing the method of imaging in order to prevent potential confusion.141,188 Reproducibility is better with SD-OCT because of the greater number of scans obtained per unit of area of retina. For the central subfield, the mean coefficients of variation of TD-OCT and SD-OCT have been reported to be 1.33 and 0.53–0.66%, respectively.184,187
OCT is an excellent tool for objectively measuring macular thickening, but macular thickening is only modestly correlated with visual acuity (r = 0.52–0.53), which is the more important clinical variable.180,189 One potential explanation for the imperfect correlation is the effect of variable duration of edema, an elusive clinical variable to define.119 Diabetes also causes apoptosis of retinal neurons before edema develops, and causes dysfunction of the glial cells of the retina, reflected in abnormalities in the electroretinogram (ERG) and
166 |
D.J. Browning |
|
|
thinning of the diabetic retina before edema develops.35 Other confounders that impair correlation of macular thickening and visual acuity include variations in macular capillary perfusion, RPE dysfunction and scarring, and media opacities. The importance of these effects in degrading visual acuity varies from case to case and for some effects varies in ways that are currently impossible to measure.35,68
Besides its usefulness in the detection of macular edema, OCT has value as a method of longitudinally following DME, a chronic disease that follows a course of years to decades, and is subject to multiple interventions over time.190 The important element in obtaining this function is the use of spreadsheet tabulation of the OCT with graphical capability (Fig. 7.29). A noncommercial program has been described using widely available spreadsheet software, and proprietary variations of this approach are appearing in electronic medical records products and the software that comes with OCT machines.190
OCT provides near histologic levels of detail in localizing edema within the retina and categorizing morphologic variations in edema. Specific cases can be seen in which cysts and edematous regions are present in any given layer of the retina, but in general
DME is characterized by thickening of the outer rather than the inner retina.68,132,178,191 Subretinal fluid has
been seen in 9.7–26.0% of eyes with DME and is not seen in the absence of neuroretinal edema.68,132,178–180
Various classifications of DME based on OCT morphology have been proposed. The most widely quoted classification proposes to grade DME into three OCT groups: sponge-like swelling, cystoid macular edema,
and subfoveal fluid; others combine these categories into hybrid subgroups.178,180 Because detection of
CME is machine dependent, the reproducibility of interclinician grading using this scale is unknown, and no consensus or standardization of OCT classifications of DME has been achieved, the proposed scales are considered to be provisional.
Fig. 7.29 Longitudinal plot of change in central subfield macular thickness (CSMT) in micrometers (top panel) and total macular volume (TMV) in mm3 (bottom panel) of a patient with diabetic macular edema followed over 29 months. The short arrow indicates argon laser focal/grid laser treatment. The long arrow indicates vitrectomy, internal limiting membrane peeling. The longitudinal display
allows easier recognition of signal (true changes in macular thickness) from noise (measurement variability, diurnal variation in macular thickness, and short-term variation in macular thickness). In addition, this format provides visualization of changes in OCT indices with interventions over time, a perspective difficult to achieve by flipping through sequential snapshot OCT images
